Trial Information

Summary: Pharmacotherapy of High-Risk Bipolar Disorder

The Department of Neuroscience at the New York State Psychiatric Institute is conducting a research study on the prevention of suicidal behavior in Bipolar Disorder using medications, and is looking for people interested in participating. The goal of our study is to compare the effect of Lithium versus Depakote (valproate) on the vulnerability to suicidal behavior during a 24-month period following either a Major Depressive Episode or a Mixed Episode. Both Lithium and Depakote are mood stabilizers which have been approved by the Food and Drug Administration (FDA) for the treatment of Bipolar Disorder. We are offering free outpatient medication monitoring visits at the Neuroscience Clinic for a period of up to 24 months.

If you are interested, or have a family member who is suffering from Bipolar Disorder, and would like further information, please call Lucia at 212-543-6216.

Partial Inclusion Criteria:

• Between 18 and 75 years old
• Currently in a Major Depressive or Mixed Episode
• History of a past suicide attempt
• Must live within the New York City metro area, since patients are required to come in regularly for psychopharmacological treatment visits

Partial Exclusion Criteria

• Requires detoxification from alcohol or other substances
• Responded poorly to Lithium or Depakote in the past

For more information,

If you would like to learn more about participating in this study, please send an e-mail message using the form below.